The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
In a development that bolsters treatment options for lymphoma, AbbVie and Genmab announced positive Phase 3 results from the EPCORE DLBCL-4 trial evaluating epcoritamab in combination with lenalidomide. The data showed a statistically significant improvement in progression-free survival, reducing the risk of disease progression by up to 60% compared to standard of care.
Sign in to access this content
Sign InPer market data, AbbVie shares closed at $251.52 (June 26, 2026), while Genmab closed at $26.12. The positive results strengthen the companies' positions in the competitive oncology market, particularly for relapsed/refractory DLBCL.
Investors are now watching for potential regulatory submissions to the FDA and other authorities, which could drive further upside. The market will also focus on full data disclosures and commercialization plans.